Previous 10 | Next 10 |
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, May 13, 2024, to review first-quarter 2024 results. During the webcast and conference call, senior leaders will provide an overview o...
2024-04-06 08:38:09 ET More on Johnson & Johnson Johnson & Johnson: Self-Proclaimed 'Dividend King' Faces Tricky Outlook With Lawsuit And Medtech Tailwinds - Johnson & Johnson May Be Back Johnson & Johnson (JNJ) Barclays 26th Annual Global Healthcare ...
New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FDA) has approved CA...
2024-03-19 11:47:20 ET More on Legend Biotech Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade) Johnson & Johnson wins FDA AdCom backing for Carvykti label expansion Legend Biotech FY 2023 Earnings Preview Read the full artic...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today released its inaugural Environmental, Social & Governance (ESG) report . The inaugural report provides an overview of Legend Biotech’s ESG program and reporting in alignment with the ...
2024-03-16 07:58:13 ET More on Bristol-Myers, 2seventy bio, etc. Bristol-Myers Squibb Company (BMY) Barclays 26th Annual Global Healthcare Conference (Transcript) Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conf...
FDA ODAC votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTI based on results from the Phase 3 CARTITUDE-4 study Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that the U.S. Food and Drug Administration (FD...
2024-03-15 13:25:53 ET More on J&J, Legend Biotech, etc. Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade) Johnson & Johnson (JNJ) Barclays 26th Annual Global Healthcare Conference (Transcript) Johnson & Johnson (JNJ) Leerink P...
2024-03-15 06:15:42 ET Summary Legend Biotech's share price is little changed despite concerns raised by the FDA in AdCom briefing documents. The increased rate of early deaths in the CARTITUDE-4 trial could reduce the use of Carvykti in later lines of multiple myeloma. Carved...
2024-03-13 09:23:45 ET More on Bristol-Myers, Johnson & Johnson, etc. Johnson & Johnson (JNJ) Leerink Partners Global Biopharma Conference (Transcript) Bristol-Myers Squibb: Finally Trending Up Bristol-Myers Squibb: Turnaround Expected J&J submits...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...